Gvoke Vialdx

For the treatment of severe hypoglycemia, the standard adult dose is 1 mg. This can be administered via subcutaneous (under the skin), intramuscular (into the muscle), or intravenous (into the vein) injection. If using the nasal powder formulation, the dose is 3 mg (one single-use device) administered into one nostril. If the patient does not respond within 15 minutes, a second dose may be administered while waiting for emergency medical services to arrive.

For diagnostic use (to inhibit GI motility), the dose varies based on the procedure and the desired duration of effect. Typical doses range from 0.25 mg to 2 mg given intravenously or intramuscularly. For example, a dose of 0.25 mg to 0.5 mg IV provides rapid onset (1 minute) with a short duration (9-17 minutes), whereas 1 mg IM provides a slower onset (4-10 minutes) but a longer duration (12-32 minutes).

Pediatric dosing for severe hypoglycemia is generally based on weight or age:

• Children weighing less than 20 kg (44 lbs): The recommended dose is 0.5 mg or a weight-based dose of 20-30 mcg/kg.
• Children weighing 20 kg or more: The standard dose is 1 mg, the same as the adult dose.
• Nasal Powder (Baqsimi): The 3 mg dose is approved for pediatric patients aged 4 years and older.

Renal Impairment

No specific dosage adjustments are required for patients with renal (kidney) impairment. However, since the kidneys contribute to the clearance of glucagon, the duration of effect might be slightly prolonged in patients with end-stage renal disease.

Hepatic Impairment

No dosage adjustment is typically necessary for hepatic (liver) impairment. However, Glucagon relies on liver glycogen stores to work. In patients with severe liver disease or cirrhosis, Glucagon may be significantly less effective or completely ineffective because the liver cannot store or release glucose.

Elderly Patients

Clinical studies have not identified significant differences in safety or effectiveness between patients over 65 and younger patients. Caution is advised in elderly patients with underlying cardiac disease, as Glucagon can cause a transient increase in heart rate and blood pressure.

Emergency Administration (Hypoglycemia)

1. 1Position the Patient: If the patient is unconscious, turn them on their side (the recovery position) to prevent choking if they vomit, which is a common side effect.
2. 2Prepare the Dose: If using a kit, inject the liquid into the powder vial, swirl gently until clear, and draw the liquid back into the syringe. If using an auto-injector or nasal spray, follow the device-specific instructions (no priming is needed for the nasal spray).
3. 3Inject: Administer into the outer thigh, upper arm, or abdomen.
4. 4Call for Help: Always call 911 or emergency services immediately after administering Glucagon.
5. 5Follow-up: As soon as the patient is conscious and able to swallow, give them a fast-acting source of sugar (like fruit juice) followed by a long-acting snack (like crackers with cheese or peanut butter).

Storage

Store Glucagon at room temperature (20°C to 25°C / 68°F to 77°F). Do not freeze. Keep the medication in its original packaging to protect it from light. Always check the expiration date; Glucagon is an emergency medication and must be replaced before it expires.

Glucagon is used on an 'as-needed' basis for emergencies or diagnostic procedures. There is no regular dosing schedule, so missed doses are not applicable. However, if a patient with diabetes does not have their Glucagon kit available during a severe hypoglycemic event, it is a medical emergency requiring immediate 911 intervention.

Signs of a Glucagon overdose include severe nausea, projectile vomiting, increased blood pressure, and a rapid heart rate. In some cases, it may cause a decrease in serum potassium (hypokalemia). Because Glucagon has a very short half-life, treatment is primarily supportive, focusing on hydration and monitoring electrolyte levels. If you suspect an overdose, contact a poison control center or seek emergency medical care.

> Important: Follow your healthcare provider's dosing instructions and ensure that family members, roommates, or coworkers are trained on how to administer Glucagon in an emergency.

The most frequent side effects associated with Glucagon administration are related to its primary physiological actions on the gastrointestinal tract and the metabolic system.

• Nausea: This is the most common side effect, occurring in up to 30% of patients. It is often described as a sudden feeling of sickness in the stomach.
• Vomiting: Frequently follows nausea. Because of the risk of vomiting while unconscious, patients should always be placed on their side (the recovery position) before or immediately after administration to prevent aspiration (breathing vomit into the lungs).
• Headache: A dull or throbbing sensation in the head, likely caused by rapid changes in blood glucose levels or the drug's effect on blood vessels.

• Tachycardia (Fast Heart Rate): Patients may feel their heart racing or pounding in their chest. This is usually transient and resolves as the drug is cleared from the system.
• Hypertension (High Blood Pressure): A temporary increase in blood pressure may occur, which is generally not clinically significant in healthy individuals but requires caution in those with pre-existing heart conditions.
• Injection Site Reactions: Redness, swelling, or minor pain at the site where the needle entered the skin.
• Nasal Congestion and Irritation: Specific to the nasal powder formulation, patients may experience a runny nose, watery eyes, or an itchy sensation in the nose and throat.

• Hypokalemia: A drop in blood potassium levels. Glucagon can cause potassium to move from the blood into the cells, which may cause muscle weakness or heart rhythm disturbances in susceptible individuals.
• Hypersensitivity Reactions: While rare, some patients may develop a rash or hives (urticaria) shortly after administration.
• Necrolytic Migratory Erythema (NME): This is a specific, painful red rash. While typically associated with glucagon-secreting tumors (glucagonomas), there have been isolated reports of skin reactions with repeated exogenous administration.

> Warning: Stop taking Glucagon and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis (Severe Allergic Reaction): Symptoms include swelling of the face, lips, or tongue, difficulty breathing, wheezing, a rapid drop in blood pressure, and fainting. This is a life-threatening emergency.
• Secondary Hypoglycemia: In patients with certain rare tumors (insulinomas), Glucagon may initially raise blood sugar but then trigger a massive release of insulin, causing blood sugar to crash even lower than before. This requires immediate hospital monitoring.
• Severe Hypertension: A massive spike in blood pressure that can cause a severe headache, blurred vision, or confusion, particularly in patients with a hidden tumor called a pheochromocytoma.

Glucagon is not intended for chronic, daily use. However, in rare cases where it is used more frequently (such as in some investigational pump therapies), potential long-term concerns include:

• Desensitization: The liver may become less responsive to glucagon if it is used too frequently, reducing its effectiveness in emergencies.
• Weight Changes: While not a direct effect of the drug, frequent severe hypoglycemia requiring glucagon can lead to 'rebound' overeating and weight gain over time.

No FDA black box warnings for Glucagon. However, it carries significant warnings regarding its use in patients with pheochromocytoma or insulinoma, which are detailed in the 'Warnings' section of this guide.

Report any unusual symptoms or side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Glucagon is a life-saving medication, but it must be used with caution in specific clinical scenarios. The most critical warning is that Glucagon is ineffective in patients whose liver glycogen stores are depleted. This includes individuals who are in a state of starvation, those with adrenal insufficiency (Addison's disease), and those suffering from chronic alcoholism. In these patients, there is no stored sugar for the Glucagon to release, and emergency glucose must be administered intravenously by medical professionals.

No FDA black box warnings for Glucagon.

• Pheochromocytoma Risk: Glucagon is strictly contraindicated in patients with pheochromocytoma (a rare tumor of the adrenal gland). Administration of Glucagon can stimulate the tumor to release massive amounts of catecholamines (like adrenaline), leading to a life-threatening hypertensive crisis (a sudden, severe increase in blood pressure).
• Insulinoma Risk: In patients with an insulin-secreting tumor (insulinoma), Glucagon can stimulate the tumor to release insulin. While the Glucagon will initially raise blood sugar, the resulting insulin spike may cause severe, prolonged hypoglycemia. If a patient does not wake up after Glucagon, they may be experiencing this secondary drop.
• Allergic Reactions: Patients with a known hypersensitivity to glucagon or any of the inactive ingredients (such as lactose in some formulations) should not use this medication. Anaphylaxis is rare but possible.
• Necrolytic Migratory Erythema (NME): This skin condition has been reported with glucagon infusion. If a healthcare provider notices a spreading, blistering rash, the medication should be discontinued.
• Cardiac Stress: Because Glucagon increases heart rate and the force of heart contractions, it should be used cautiously in patients with known coronary artery disease or heart failure.

• Blood Glucose: Continuous or frequent finger-stick blood glucose monitoring is required after administration to ensure the patient is recovering and to detect rebound hypoglycemia.
• Vital Signs: In a clinical setting (such as during a diagnostic exam), heart rate and blood pressure should be monitored.
• Electrolytes: In cases of high-dose use or overdose, serum potassium levels should be checked to monitor for hypokalemia.

Patients should not drive or operate heavy machinery until they have fully recovered from the hypoglycemic event and their blood sugar has stabilized. The hypoglycemia itself, rather than the Glucagon, is the primary cause of impairment. However, since Glucagon can cause nausea and dizziness, wait until all side effects have subsided.

Alcohol consumption significantly interferes with the liver's ability to produce and release glucose. Chronic alcohol use depletes glycogen stores, making Glucagon ineffective. Even acute alcohol consumption (binge drinking) can block the liver's response to Glucagon. Patients who have been drinking alcohol may require IV glucose instead of Glucagon to treat a low.

There are no tapering requirements for Glucagon as it is an acute-use medication. There is no risk of a withdrawal syndrome. However, after using Glucagon, patients must review their diabetes management plan with their doctor to determine why the severe low occurred and how to prevent future episodes.

> Important: Discuss all your medical conditions, especially any history of tumors or liver disease, with your healthcare provider before an emergency arises.

While there are no drugs that are strictly 'contraindicated' in a way that prevents emergency use, there are combinations that significantly alter the safety profile:

• Pheochromocytoma-related medications: Any drug that further increases catecholamine levels should be avoided, though the primary contraindication is the underlying condition itself.

• Beta-Blockers (e.g., Propranolol, Atenolol): Patients taking beta-blockers may have an exaggerated increase in both pulse and blood pressure when given Glucagon. This is due to the 'unopposed' alpha-adrenergic effect. The increase is usually temporary but can be significant in patients with heart disease.
• Indomethacin: This nonsteroidal anti-inflammatory drug (NSAID) can interfere with Glucagon's ability to raise blood sugar. In some cases, indomethacin may actually cause Glucagon to produce hypoglycemia instead of hyperglycemia by interfering with the liver's glucose release mechanism.

• Warfarin: Glucagon may enhance the anticoagulant (blood-thinning) effect of warfarin. While a single emergency dose is unlikely to cause major bleeding, patients on chronic warfarin therapy should have their INR (International Normalized Ratio) monitored more closely if they require repeated doses of Glucagon.
• Insulin: Insulin and Glucagon are physiological antagonists. While they are often used together in 'bi-hormonal' pumps, in an emergency, the presence of excessive insulin is what Glucagon is trying to overcome. High doses of insulin will require higher or repeated doses of Glucagon.

• Lack of Carbohydrates: Glucagon's effectiveness is entirely dependent on the presence of carbohydrates stored in the liver (glycogen). If a patient has been fasting or is malnourished, Glucagon will not work.
• Alcohol: As mentioned previously, alcohol inhibits gluconeogenesis and depletes glycogen, making Glucagon ineffective.

There are no well-documented interactions between Glucagon and common herbal supplements like St. John's Wort or Ginkgo Biloba. However, any supplement that affects blood sugar (such as berberine or high doses of cinnamon) could theoretically influence the overall glycemic state, but they do not interact with the Glucagon molecule itself.

Glucagon administration can temporarily affect certain laboratory results:

• Blood Glucose: Will be significantly elevated (the intended effect).
• Serum Potassium: May be temporarily decreased.
• Ketones: Glucagon can increase the production of ketones, which might be confusing in the context of diabetic ketoacidosis (DKA) monitoring.

For each major interaction, the management strategy is generally the same: prioritize the emergency treatment of hypoglycemia first, then monitor the patient closely for cardiovascular changes or rebound blood sugar issues.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you have a history of heart disease or are on blood thinners.

There are three primary conditions where Glucagon must NEVER be used:

1. 1Pheochromocytoma: This is a tumor of the adrenal gland. Glucagon stimulates the tumor to release catecholamines (epinephrine and norepinephrine), which can cause a sudden, catastrophic rise in blood pressure, potentially leading to a stroke or heart attack.
2. 2Insulinoma: This is an insulin-producing tumor. Glucagon can stimulate the tumor to release a massive amount of insulin. While the blood sugar might rise for a few minutes, the insulin surge will cause it to drop to dangerously low levels shortly after, which can be fatal if not recognized.
3. 3Known Hypersensitivity: If a patient has had a documented severe allergic reaction (anaphylaxis) to Glucagon or any component of the formulation (like lactose or glycerin), it should not be used.

These are conditions where the benefit of saving a life from hypoglycemia usually outweighs the risk, but medical supervision is required:

• Glucagonoma: A tumor that already secretes glucagon. Adding more exogenous glucagon can worsen the symptoms of the tumor, such as severe skin rashes and high blood sugar.
• Severe Cardiac Disease: Because Glucagon increases the workload of the heart, it should be used with extreme caution in patients with unstable angina or recent myocardial infarction (heart attack).
• Adrenal Insufficiency: In patients with Addison's disease, the lack of cortisol means they have very low glycogen stores. Glucagon is unlikely to work, and they require IV dextrose and hydrocortisone.

There are no common cross-sensitivities with other drug classes, as Glucagon is a unique peptide hormone. However, patients with a severe 'dairy allergy' should check their specific Glucagon formulation, as some powders use lactose as a stabilizing agent.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of rare tumors, before prescribing an emergency Glucagon kit.

Glucagon is generally considered safe for use during pregnancy. According to the FDA, it is classified as a medication that should be used if clearly needed. Because Glucagon is a large peptide hormone, it does not cross the placenta in significant amounts and is not expected to harm the developing fetus. Severe hypoglycemia in the mother is a much greater risk to the baby (potentially causing fetal distress or death) than the medication itself. There is no known evidence of teratogenicity (birth defects) in humans.

It is not known if Glucagon is excreted in human breast milk. However, even if it were, Glucagon is a protein that is rapidly broken down in the digestive tract. If an infant were to ingest Glucagon through breast milk, it would be digested like any other dietary protein and would not be absorbed into the infant's bloodstream. Therefore, Glucagon is considered compatible with breastfeeding. No special precautions are typically required for nursing mothers.

Glucagon is FDA-approved for use in children of all ages for the treatment of severe hypoglycemia. The dose is adjusted based on weight (0.5 mg for <20 kg, 1 mg for >20 kg). The nasal formulation (Baqsimi) is approved for children 4 years of age and older. Clinical trials have shown that the safety profile in children is similar to that in adults, with nausea and vomiting being the most frequent side effects. It is critical that school nurses, teachers, and coaches are trained in its administration.

Clinical studies of Glucagon did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients with pre-existing heart disease may be at higher risk for the tachycardic (fast heart rate) effects of Glucagon.

The kidneys are responsible for approximately 30% of Glucagon clearance. In patients with renal impairment or kidney failure, the half-life of Glucagon may be slightly prolonged. However, because it is used as a single emergency dose, no dosage adjustment is recommended. The clinical effect may last slightly longer, which is generally not harmful in the context of treating low blood sugar.

Hepatic (liver) impairment does not change the way Glucagon is cleared, but it significantly changes how the drug works. Glucagon requires the liver to have stores of glycogen. In patients with end-stage liver disease or cirrhosis, the liver may be unable to respond to Glucagon. These patients must be treated with IV glucose. No dose adjustment is needed, but healthcare providers should be aware of the high risk of treatment failure.

> Important: Special populations require individualized medical assessment. Ensure your 'Diabetes Emergency Plan' accounts for these factors.

Glucagon is an agonist at the glucagon receptor, a G-protein-coupled receptor located primarily on hepatocytes. Upon binding, it activates adenylate cyclase, which increases intracellular levels of cyclic AMP (cAMP). This 'second messenger' activates protein kinase A (PKA), which then phosphorylates and activates the enzyme phosphorylase kinase. This enzyme, in turn, activates glycogen phosphorylase, the rate-limiting enzyme that converts glycogen into glucose-1-phosphate, which is then converted to free glucose and released into the blood. This process is known as glycogenolysis.

The pharmacodynamic response to Glucagon is a rapid rise in blood glucose. Following a 1 mg IM injection, blood glucose typically begins to rise within 5 to 10 minutes and reaches a peak increase of approximately 20-50 mg/dL within 30 minutes. The duration of the hyperglycemic effect is approximately 60 to 90 minutes. In the GI tract, the pharmacodynamic effect is smooth muscle relaxation, which occurs within 1 minute of an IV injection and lasts up to 20 minutes depending on the dose.

| Parameter | Value |

|---|---|

| Bioavailability | High (IM/SC); ~100% relative to IV |

| Protein Binding | Negligible |

| Half-life | 8 to 18 minutes |

| Tmax (Injection) | 10 to 15 minutes |

| Tmax (Nasal) | 30 minutes |

| Metabolism | Proteolysis in Liver, Kidney, and Plasma |

| Excretion | Renal (30%), Hepatic (70%) |

• Molecular Formula: C153H225N43O49S
• Molecular Weight: 3482.8 g/mol
• Solubility: Soluble in water at pH < 3 or > 9.5.
• Structure: Glucagon is a single-chain polypeptide containing 29 amino acid residues. It is identical in structure to human pancreatic glucagon.

Glucagon is classified as an Antihypoglycemic Agent and a Gastrointestinal Motility Inhibitor. It is the only member of its class used for emergency hypoglycemia, though newer 'glucagon-like' analogs (such as dasiglucagon) have recently been developed to provide more stable liquid formulations.